At a glance

ClinicalIndex Comparison Record

Phase 4Completed

Drug / intervention

Pegylated interferon alpha 2 +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00241618

NCT00241618Phase 4Completed

Compare CT.gov

Phase IV Study of Treatment of Acute Hepatitis C With Pegylated Interferon

Ain Shams University·interventional·Posted Oct 19, 2005·Updated Sep 11, 2006

In Brief

A Phase 4 clinical trial evaluating Pegylated interferon alpha 2 and Ribavirin for Hepatitis C. Completed, across 3 sites.

Detailed Summary

Spontaneous resolution of acute hepatitis C infection cannot be predicted and the majority of cases persist and become chronic. This randomized trial assesses the efficacy and safety of peginterferon alfa-2b. The investigators hypothesize that therapy strategies could prevent the development of chronic hepatitis.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHepatitis C

CountriesEgypt

CollaboratorsUniversity Hospital Freiburg, Beth Israel Deaconess Medical Center, Alexander von Humboldt Association, Fulbright, National Institute of Allergy and Infectious Diseases (NIAID), Tempus AI, International Society for Infectious Diseases

Timeline

Phase 4CompletedFinished

20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJan 2002

First PostedOct 2005

Study CompletionJan 2006

TodayJul 2026

First PostedOct 19, 2005

Enrollment StartJan 1, 2002

Study CompletionJan 1, 2006

TodayJul 2, 2026

Posted 20.7 years ago

Interventions

Pegylated interferon alpha 2drug

Ribavirindrug